Comprehensive metabolomic analysis identifies key biomarkers and modulators of immunotherapy response in NSCLC patients
Drug Resistance Updates · 2024-11 · 77 · 101159
DOI: 10.1016/j.drup.2024.101159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-11. Verfasst von Se-Hoon Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Depa…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor, Metabolomics. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Gwangju Institute of Science and Technology, Samsung Medical Center, Sungkyunkwan University, Korea Basic Science Institute.
Abstract (Originalsprache)
Although immune checkpoint inhibitors (ICIs) have revolutionized immuno-oncology with effective clinical responses, only 30 to 40 % of patients respond to ICIs, highlighting the need for reliable biomarkers to predict and enhance therapeutic outcomes. This study investigated how amino acid, glycolysis, and bile acid metabolism affect ICI efficacy in non-small cell lung cancer (NSCLC) patients. Through targeted metabolomic profiling and machine learning analysis, we identified amino acid metabolism as a key factor, with histidine (His) linked to favorable outcomes and homocysteine (HCys), phenylalanine (Phe), and sarcosine (Sar) linked to poor outcomes. Importantly, the His/HCys+Phe+Sar ratio emerges as a robust biomarker. Furthermore, we emphasize the role of glycolysis-related metabolites, particularly lactate. Elevated lactate levels post-immunotherapy treatment correlate with poorer outcomes, underscoring lactate as a potential indicator of treatment efficacy. Moreover, specific bile acids, glycochenodeoxycholic acid (GCDCA) and taurolithocholic acid (TLCA), are associated with better survival and therapeutic response. Particularly, TLCA enhances T cell activation and anti-tumor immunity, suggesting its utility as a predictive biomarker and therapeutic agent. We also suggest a connection between gut microbiota and TLCA levels, with the Eubacterium genus modulating this relationship. Therefore, modulating specific metabolic pathways-particularly amino acid, glycolysis, and bile acid metabolism-could predict and enhance the efficacy of ICI therapy in NSCLC patients, with potential implications for personalized treatment strategies in immuno-oncology. ONE SENTENCE SUMMARY: Our study identifies metabolic biomarkers and pathways that could predict and enhance the outcomes of immune checkpoint inhibitor therapy in NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Health Sciences and Technology, Samsung Advanced Institute o…
- Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, South Korea.
- Integrated Metabolomics Research Group, Western Seoul Center, Korea Basic Science Institute, Seoul, South Korea.
- Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea.
- The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT 06032, USA.
- Integrated Metabolomics Research Group, Western Seoul Center, Korea Basic Science Institute, Seoul, South Korea; College of Pharmacy, Chung-Ang University, Seoul 06974, South Korea. Electronic address: gshwang@kbsi.re.k…
Förderung
- Gwangju Institute of Science and Technology
- Samsung Medical Center, Sungkyunkwan University
- Korea Basic Science Institute
- National Research Foundation of Korea
- Ministry of Health and Welfare
- Korea Health Industry Development Institute
- Korea Research Environment Open Network
- Korea Institute of Science and Technology Information
Zitieren
APA
Lee, S. H., Kim, S., Lee, J., Kim, Y., Joo, Y., Heo, J. Y., Lee, H., Lee, C., Hwang, G. S., & Park, H. (2024). Comprehensive metabolomic analysis identifies key biomarkers and modulators of immunotherapy response in NSCLC patients. Drug Resistance Updates, 77, 101159. https://doi.org/10.1016/j.drup.2024.101159
Vancouver
Lee SH, Kim S, Lee J, Kim Y, Joo Y, Heo JY, et al. Comprehensive metabolomic analysis identifies key biomarkers and modulators of immunotherapy response in NSCLC patients. Drug Resistance Updates. 2024;77:101159. doi:10.1016/j.drup.2024.101159
BibTeX
@article{Lee2024,
author = {Lee, Se-Hoon and Kim, Sujeong and Lee, Jueun and Kim, Yunjae and Joo, Yanghyun and Heo, Jun-Yeong and Lee, Heeyeon and Lee, Charles and Hwang, Geum-Sook and Park, Hansoo},
title = {Comprehensive metabolomic analysis identifies key biomarkers and modulators of immunotherapy response in NSCLC patients},
journal = {Drug Resistance Updates},
year = {2024},
volume = {77},
pages = {101159},
doi = {10.1016/j.drup.2024.101159}
}
EUVIMED